A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine.
研究概览
简要总结
The purpose of this study is to gather systematic clinical data on whether aripiprazole, a partial dopamine agonist, beneficially affects schizophrenia plus cocaine dependence subjects. Since aripiprazole has established effects against schizophrenia, the study focuses on whether aripiprazole concurrently reduces co-morbid cocaine dependence in schizophrenia plus cocaine dependence sufferers compared to a standard typical antipsychotic treatment (perphenazine). The working hypothesis states that subjects in the aripiprazole treatment arm of the study will give fewer cocaine positive urine specimens as compared to the perphenazine control arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a primary DSM-IV diagnosis of Schizophrenia or Schizoaffective disorder
- •Have a DSM-IV diagnosis of current cocaine dependence.
- •Are capable of reading, comprehending, and signing informed consent.
- •Agree to take Aripiprazole or Perphenazine as treatment for SCHZ and CD.
- •Agree to stop taking any other antipsychotic medication
- •If female and of child bearing potential (WOCBP) agree to use an acceptable form of birth control and have a negative pregnancy test within 2 days prior to starting study medication
排除标准
- •Under 18 years old or over 65 years old.
- •Refusal or inability to give informed consent,
- •Have a history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities, cerebrovascular disease, or conditions that would predispose to hypotension (dehydration, hypovolemia),
- •A history of seizures or conditions that lower the seizure threshold
- •Have current suicidal ideation (history of suicide attempt in past 60 days)
- •Are actively psychotic which in the opinion of the investigator would preclude proper informed consenting or protocol adherence
- •Are receiving or plan to receive an agent metabolized by the Cytochrome P450-3A4 or -2D6 systems, including carbamazepine, ketoconazole, quinidine, fluoxetine, and paroxetine
- •WOCBP not on, or do not agree to use an acceptable form of contraception
- •Known sensitivity to aripiprazole or perphenazine
- •A diagnosis of current or past tardive dyskinesia
- •Pending legal charges or a court mandate for drug treatment
- •Currently taking concomitant medications that have been shown to reduce cocaine use, such as disulfiram
- •Clinically significant liver function abnormalities
- •Currently receiving depot neuroleptics
研究组 & 干预措施
1
干预措施: Aripiprazole (Drug)
2
干预措施: Perphenazine (Drug)
结局指标
主要结局
The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine.
时间窗: Week 3 and Week 8 of study participation
次要结局
- The mean total self-report cocaine use days will be significantly fewer in subjects treated with aripiprazole than in those treated with perphenazine.(End of study participation)
- The mean cocaine craving scores will be lower in subjects treated with aripiprazole than in those treated with perphenazine.(End of study participation)
研究者
Paul Saenger
Executive Director
Denver Research Institute